Vanguard Fiduciary Trust
TVRD

Vanguard Fiduciary Trust’s Tvardi Therapeutics TVRD Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Sell
44,710
-2,162
-5% -$6.78K ﹤0.01% 3765
2026
Q1 		$149K Buy
+46,872
New +$184K ﹤0.01% 3599

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Vanguard Fiduciary Trust's TVRD Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Tvardi Therapeutics (TVRD) stake by 4.6% in Q2 2026, selling an estimated $6.78K and leaving 44,710 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3765.

Vanguard Fiduciary Trust first reported a position in TVRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $149K in Q1 2026. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Vanguard Fiduciary Trust held 44,710 shares of Tvardi Therapeutics worth $84.9K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 2,162 Tvardi Therapeutics shares in Q2 2026, an estimated $6.78K.
  • Tvardi Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3765 holding.
  • Vanguard Fiduciary Trust first reported a position in Tvardi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Tvardi Therapeutics position peaked at $149K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.